Program
Epinephrine
Also written as “epinephrine inhalation aerosol”, “Epinephrine Nasal Spray, 2.5 mg” and “Epinephrine Nasal Spray, 5.25 mg”.
Its studies are mostly in Anaphylaxis · Asthma · Hypersensitivity · Chronic Urticaria · Respiratory Tract Infections, led by 7 companies.
Drug pageEpinephrine: every studyMany companies study it; this page follows only the 16 they lead. All 221 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amphastar Pharmaceuticalsits history only | 40 open or running | phase 4since Dec 19, 2019 | Jun 7, 2010 | none ahead |
| Nasus Pharmaits history only | 42 open or running | phase 3since Jun 8, 2025 | Dec 1, 2020 | none ahead |
| ARS Pharmaceuticalsits history only | 32 open or running | phase 4since Feb 18, 2025 | Jun 9, 2021 | Apr 2027phase 4 · NCT06834165 |
| De Motu Cordisits history only | 20 open or running | phase 1since Nov 9, 2021 | Nov 9, 2021 | none ahead |
| ALK-Abellóits history only | 10 open or running | phase 4since Jun 20, 2013 | Jun 20, 2013 | none ahead |
| Hikma Pharmaceuticalsits history only | 11 open or running | phase 2since Aug 18, 2026 | Aug 18, 2026 | May 8, 2027phase 2 · NCT07891780 |
| Smith & Nephew | 10 open or running | phase 2since Apr 5, 2017 | Apr 5, 2017 | none ahead |
Also a collaborator on its studies: Medistat Ltd., Israel, Pharma Medica Research and Novotech (Australia) Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Smith & Nephew only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 5, 2017First study: phase 2 study in Healthy VolunteerFirst studyNCT03119181 · 40 enrolled · United States
TargetBeta
“Adrenergic receptor agonist; Adrenergic receptor agonist”ChEMBL 37, by rule
Studies
The one study Smith & Nephew leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03119181Healthy Volunteer · United States | 2 | Completed | May 11, 2017 | 40 |
How it is read
Names in the registry
- “epinephrine inhalation aerosol”, 4 entries
- “Epinephrine Nasal Spray, 2.5 mg”, 1 entry
- “Epinephrine Nasal Spray, 5.25 mg”, 1 entry
- “0.5 mg epinephrine”, 1 entry
- “1 mg epinephrine”, 1 entry
Codes read as this program: FMXIN002.
Conditions, from the studies’ own filings
- Anaphylaxis, 7 studies
- Asthma, 4 studies
- Hypersensitivity, 2 studies
- Chronic Urticaria, 1 study
- Respiratory Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.